S. Korea Study Reveals High Autism Rate

An ambitious six-year effort to gauge the rate of childhood autism in a middle-class South Korean city has yielded a figure that stunned experts and is likely to influence the way the disorder’s prevalence is measured around the world, scientists reported on Monday.
The figure, 2.6 percent of all children aged 7 to 12 in the Ilsan district of the city of Goyang, is more than twice the rate usually reported in the developed world. Even that rate, about 1 percent, has been climbing rapidly in recent years — from 0.6 percent in the United States in 2007, for example.
But experts said the findings did not mean that the actual numbers of children with autism were rising, simply that the study was more comprehensive than previous ones.
"This is a very impressive study," said Lisa Croen, director of the autism research program at Kaiser-Permanente Northern California, who was not connected with the new report. "They did a careful job and in a part of the world where autism has not been well documented in the past."

A Child Regresses. Is Autism to Blame?

From the Consults Blog at The New York Times, Dr. Fred Volkmar answers a reader's question on autism.

If a young child suddenly stops speaking, is autism to blame? That is among the questions recently posed by readers of the Consults blog. Here, Dr. Fred Volkmar, director of the Yale Child Study Center, explores the issue of regression in children and the diagnosis of autism.

Study Scrutinizes Autism Treatments

Three new studies conclude that many widely used behavioral and medication treatments for autism have some benefit, one popular alternative therapy doesn't help at all, and there isn't yet enough evidence to discern the best overall treatment.
Parents of children with autism-spectrum disorder often try myriad treatments, from drugs to therapy to nutritional supplements. The studies being published Monday and funded by the federal Agency for Healthcare Research and Quality, were part of the effort to examine the comparative effectiveness of treatments in 14 priority disease areas, including autism-spectrum disorders.